Compagnie Lombard Odier SCmA Invests $561000 in Regeneron (REGN) Stock

Sunday, 15 Apr, 2018

The institutional investor held 64,378 shares of the health care company at the end of 2017Q4, valued at $24.20M, up from 55,717 at the end of the previous reported quarter. Polen Capital Management Llc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $34.60B market cap company. The stock increased 0.54% or $0.43 during the last trading session, reaching $79.72. About 570,074 shares traded or 35.24% up from the average. Verizon Communications Inc. (NYSE:VZ) has declined 3.72% since April 15, 2017 and is downtrending. It has underperformed by 6.09% the S&P500. (NASDAQ:REGN). Blume Cap Mgmt reported 0.02% of its portfolio in Regeneron Pharmaceuticals, Inc. Cornercap Investment Counsel Inc bought 9,515 shares as the company's stock declined 11.06% with the market. Jefferies Group reaffirmed a "hold" rating and set a $380.00 target price on shares of Regeneron in a report on Thursday, February 8th. Vanguard Group Inc has invested 0.09% in Regeneron Pharmaceuticals, Inc. 704,764 shares of the company traded hands. (NASDAQ:REGN). Cibc Markets has invested 0% in Regeneron Pharmaceuticals, Inc. It has underperformed by 25.74% the S&P500. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $13.02 EPS for the current year. (NASDAQ:REGN) by 45.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Therefore 36% are positive. (NASDAQ:REGN) on Monday, April 9 to "Market Perform" rating. The company was downgraded on Friday, April 1 by Moffet Nathanson. Cowen reiterated a "hold" rating and issued a $450.00 price target on shares of Regeneron in a research note on Wednesday, February 7th. Bank of America maintained the stock with "Buy" rating in Wednesday, January 24 report. The firm has "Hold" rating by Jefferies given on Monday, June 5. On Thursday, November 9 RBC Capital Markets maintained Regeneron Pharmaceuticals, Inc. The rating was downgraded by Zacks on Wednesday, September 2 to "Sell". J P Morgan Chase & Co set a $440.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a "hold" rating in a research note on Sunday, November 6th. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Nippon Life Americas invested 1.1% of its portfolio in Regeneron Pharmaceuticals, Inc. The rating was initiated by Piper Jaffray with "Buy" on Thursday, September 28.

North Star Asset Management Inc decreased its stake in Ca Technologies (CA) by 9.73% based on its latest 2017Q4 regulatory filing with the SEC. It also reduced its holding in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 7,905 shares in the quarter, leaving it with 1,000 shares, and cut its stake in Digimarc Corp New (NASDAQ:DMRC).

The institutional investor purchased 1,493 shares of the biopharmaceutical company's stock, valued at approximately $561,000. The ratio has no change due to REGN positioning: 62 sold and 161 reduced. only 71 funds amassed positions and 191 increased positions. Cypress Asset Management Tx holds 7,131 shs or 0.58% of its capital. (NYSE:VZ). High Pointe Capital Mngmt Ltd accumulated 17,640 shares or 1.27% of the stock. Sumitomo Mitsui Asset Ltd reported 5,684 shs. Citigroup reported 42,872 shares. Baillie Gifford & owns 0% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Moreover, Tiaa Cref Inv Management Lc has 0.06% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Bartlett Comm Lc invested in 0% or 40 shs. Assetmark reported 0% in Regeneron Pharmaceuticals, Inc.

Shares of REGN stock opened at $321.56 on Wednesday. National Bank Of Nova Scotia holds 25,253 shares. State Street Corp now owns 3,240,549 shares of the biopharmaceutical company's stock worth $1,189,574,000 after buying an additional 68,675 shares during the period. (NASDAQ:REGN). Vident Investment Advisory Ltd Liability reported 0.04% of its portfolio in Regeneron Pharmaceuticals, Inc. California-based Franklin Res has invested 0.15% in Regeneron Pharmaceuticals, Inc. (NASDAQ:PCLN). Thompson Siegel And Walmsley Limited Company reported 152 shares or 0% of all its holdings.

Investors sentiment increased to 1.02 in Q4 2017. Its down 0.68, from 1.58 in 2017Q3. 36 funds opened positions while 60 raised stakes. Pinebridge Ltd Partnership reported 0.45% stake. Whittier Trust holds 0% or 100 shares in its portfolio. Payden And Rygel accumulated 195,900 shares. Intersect Llc invested 0.33% in Eli Lilly and Company (NYSE:LLY). (NASDAQ:REGN) for 227,901 shares. Moreover, Macquarie Gp has 0% invested in NRG Energy, Inc. Investors holded 73.70 million in 2017Q3 but now own 69.17 million shares or 6.15% less. Millennium Mgmt Limited Liability Corp invested in 478,244 shares. 10,431 are held by Amalgamated Bank & Trust. Optimum Investment Advsr holds 0.24% in Booking Holdings Inc. (NASDAQ:BPOP). Cadence Capital Ltd Llc invested 0.04% in Popular, Inc. Conning reported 0.07% of its portfolio in Eli Lilly and Company (NYSE:LLY).

Among 16 analysts covering CA Technologies (NASDAQ:CA), 2 have Buy rating, 4 Sell and 10 Hold. Therefore 33% are positive.

Since October 16, 2017, it had 0 buys, and 6 insider sales for $9.77 million activity. SunTrust maintained the shares of VZ in report on Tuesday, January 23 with "Hold" rating. The firm has "Overweight" rating given on Friday, April 8 by Piper Jaffray. The company was downgraded on Monday, January 25 by Chardan Capital Markets. The firm has "Overweight" rating by Barclays Capital given on Tuesday, December 1. Wood upgraded the stock to "Outperform" rating in Tuesday, November 28 report. The firm has "Buy" rating by UBS given on Monday, September 7.

Clearbridge Investments Llc, which manages about $108.23 billion US Long portfolio, decreased its stake in Stanley Black & Decker Inc (NYSE:SWK) by 194,077 shares to 443,374 shares, valued at $75.24 million in 2017Q4, according to the filing.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.